← Back to Patent Explorer
US4440770A Expired / Lapsed US ⏱️ 0.0 years remaining

Diuretic, hypotensive and antiedemic quinoline oximes

Assignee: Hodogaya Chemical Co Ltd
•
Filing: 1981-07-07
•
Granted: 1984-04-03
•
Expires: 2001-07-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical composition having diuretic, hypotensive and antiedemic effects which contains a 6-halo-4-oximino-1,2,3,4-tetrahydroquinoline derivative or a salt thereof, and a method to use the above-described derivative or a salt thereof as a diuretic, hypotensive and antiedemic agent.

Inventors

  • 👤 Ei Mochida
  • 👤 Haruo Ohnishi
  • 👤 Kazuo Yamaguchi
  • 👤 Yasuo Suzuki
  • 👤 Hiroshi Kosuzume

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 23:58
CPC Classifications
C; C07; C07D; C07D215/00; C07D215/02; C07D215/16; C07D215/38; C07D215/42; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 72 words
A pharmaceutical composition containing a diuretic, hypotensive and antiedemic effective amount of a 6-halo-4-oximino-1,2,3,4-tetrahydroquinoline derivative of the formula (I): ##STR3## or a salt thereof, wherein X represents a halogen atom, and Y represents a straight-chain or branched-chain alkyl group having 1-4 carbon atoms, a phenyl-substituted lower alkyl group, a phenylalkenyl group, a lower alkoxy group or a lower alkyl-substituted amino group, as an active ingredient together with a conventional pharmaceutically acceptable additive.
Claim 2
Dependent Claim 72 words
A pharmaceutical composition containing a diuretic, hypotensive and antiedemic effective amount of a 6-halo-4-oximino-1,2,3,4-tetrahydroquinoline derivative of the formula (I): ##STR3## or a salt thereof, wherein X represents a halogen atom, and Y represents a straight-chain or branched-chain alkyl group having 1-4 carbon atoms, a phenyl-substituted lower alkyl group, a phenylalkenyl group, a lower alkoxy group or a lower alkyl-substituted amino group, as an active ingredient together with a conventional pharmaceutically acceptable additive.
Claim 3
Dependent Claim 23 words
The pharmaceutical composition according to claim 1 which contains 1.0-99.9% by weight of the active ingredient and 99.0-0.1% by weight of the additive.
Claim 4
Dependent Claim 23 words
The pharmaceutical composition according to claim 1 which contains 5-70% by weight of the active ingredient and 95-30% by weight of the additive.
Claim 5
Dependent Claim 46 words
The pharmaceutical composition according to claim 1, 2 or 3 in which the active ingredient is selected from the group consisting of 6-chloro-4-oximino-1-acetyl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-propionyl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-butyryl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-isobutyryl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-valeryl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-isovaleryl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-phenylacetyl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-cinnamoyl-1,2,3,4-tetrahydroquinoline, 6-fluoro-4-oximino-1-methoxycarbonyl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-methoxycarbonyl-1,2,3,4-tetrahydroquinoline, 6-bromo-4-oximino-1-methoxycarbonyl-1,2,3,4-tetrahydroquinoline, 6-fluoro-4-oximino-1-ethoxycarbonyl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-ethoxycarbonyl-1,2,3,4-tetrahydroquinoline, 6-bromo-4-oximino-1-acetyl-1,2,3,4-tetrahydroquinoline, 6-fluoro-4-oximino-1-propionyl-1,2,3,4-tetrahydroquinoline, 6-bromo-4-oximino-1-propionyl-1,2,3,4-tetrahydroquinoline, 6-bromo-4-oximino-1-isobutyryl-1,2,3,4-tetrahydroquinoline, 6-bromo-4-oximino-1-cinnamoyl-1,2,3,4-tetrahydroquinoline, 6-choro-4-oximino-1-methylcarbamoyl-1,2,3,4-tetrahydroquinoline, 6-bromo-4-oximino-1-methylcarbamoyl-1,2,3,4-tetrahydroquinoline. 6-fluoro-4-oximino-1-dimethylcarbamoyl-1,2,3,4-tetrahydroquinoline, 6-chloro-4-oximino-1-dimethylcarbamoyl-1,2,3,4-tetrahydroquinoline, and 6-bromo-4-oximino-1-dimethylcarbamoyl-1,2,3,4-tetrahydroquinoline.
Claim 6
Dependent Claim 33 words
The pharmaceutical composition according to any of claims 1-4 in which the additive is selected from the group consisting of Tween 80, arabic gum, lactose, magnesium stearate, potato starch, polyvinylalcohol and polyethylene glycol.
Claim 7
Dependent Claim 36 words
The pharmaceutical composition according to any of claims 1-5 which is in the form selected from the group consisting of an oral dosage form, a rectal dosage form, an injectable form and a topical application form.
Claim 8
Independent Claim 83 words
A method for treating a disease selected from the group consisting of hypertension and edema which comprises administering to a human body needing treatment for such a disease an effective amount of a 6-halo-4-oximino-1,2,3,4-tetrahydroquinoline derivative of the formula (I): ##STR4## or a pharmaceutically acceptable salt thereof, wherein X represents a halogen atom, and Y represents a straight-chain or branched-chain alkyl group having 1-4 carbon atoms, a phenyl-substituted lower alkyl group, a phenylalkenyl group, a lower alkoxy group or a lower alkyl-substituted amino group.
Claim 9
Independent Claim 83 words
A method for treating a disease selected from the group consisting of hypertension and edema which comprises administering to a human body needing treatment for such a disease an effective amount of a 6-halo-4-oximino-1,2,3,4-tetrahydroquinoline derivative of the formula (I): ##STR4## or a pharmaceutically acceptable salt thereof, wherein X represents a halogen atom, and Y represents a straight-chain or branched-chain alkyl group having 1-4 carbon atoms, a phenyl-substituted lower alkyl group, a phenylalkenyl group, a lower alkoxy group or a lower alkyl-substituted amino group.
Claim 10
Dependent Claim 32 words
The method according to claim 7 in which the daily dose of the compound of the formula (I) or the salt thereof is in the range of 1 mg to 10 g.
Claim 11
Dependent Claim 32 words
The method according to claim 8 in which the daily dose of the compound of the formula (I) or a salt thereof is in the range of 5 mg to 6 g.
Claim 12
Dependent Claim 29 words
The method according to claim 7, 8 or 9 in which the compound of the formula (I) or a salt thereof is administered orally, intrarectally, by injection or topically.
Claim 13
Independent Claim 84 words
A method for treating a disease selected from the group consisting of hypertension and edema which comprises administering to a human body needing treatment for such a disease an effective amount of a composition comprising a carrier and a compound of the formula (I) ##STR5## wherein X represents a halogen and Y represents a straight-chain or branched chain alkyl having 1-4 carbon atoms, a phenyl-substituted lower alkyl, a phenylalkenyl, a lower alkoxy or a lower alkyl-substituted amino group, or a pharmaceutically acceptable salt thereof.
Claim 14
Independent Claim 84 words
A method for treating a disease selected from the group consisting of hypertension and edema which comprises administering to a human body needing treatment for such a disease an effective amount of a composition comprising a carrier and a compound of the formula (I) ##STR5## wherein X represents a halogen and Y represents a straight-chain or branched chain alkyl having 1-4 carbon atoms, a phenyl-substituted lower alkyl, a phenylalkenyl, a lower alkoxy or a lower alkyl-substituted amino group, or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim 32 words
The method according to claim 11 in which the daily dose of the compound of the formula (I) or the salt thereof is in the range of 1 mg to 10 g.
Claim 16
Dependent Claim 32 words
The method according to claim 12 in which the daily dose of the compound of the formula (I) or a salt thereof is in the range of 5 mg to 6 g.
Claim 17
Dependent Claim 29 words
The method according to claim 11, 12 or 13 in which the compound of the formula (I) or a salt thereof is administered orally, intrarectally, by injection or topically.

References Cited (Backward Citations)

JPS51122719A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-04-03 1987-10-03 1988-04-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-04-03 1991-10-03 1992-04-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-04-03 1995-10-03 1996-04-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag